BMJ (Clinical research ed.)|2025|Brown C
PMID: 41203407
A GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management.
PURPOSE: Patients with type II diabetes mellitus are at greater risk of carpal tunnel syndrome and of complications following carpal tunnel release (CTR). Although recent orthopedic literature suggests preoperative semaglutide use may reduce complica…
PURPOSE: This systematic review was conducted to determine which type of oral medication for obesity provides the best weight loss effect. METHODS: This study adhered to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guid…
Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD). We conducted a randomized placebo-controlled double-blind clinical trial in adults with CKD (estimated glome…
BACKGROUND: The treatment of obesity and type 2 diabetes (T2D) in Prader-Willi syndrome (PWS) is still a challenge. Glucagon-like peptide 1 receptor agonists (GLP-1 RA) are attractive options, since they effectively reduce weight and improve blood gl…
GLP-1 agonists have been a welcome addition to the armamentarium in the treatment of diabetes and obesity. While this class of medications is generally considered safe and effective, potentially severe neurological complications may be associated wit…
BACKGROUND: Obesity is a global public health challenge. Pharmacological interventions, such as glucagon-like peptide-1 (GLP-1) receptor agonists (eg, semaglutide) and dual GLP-1/gastric inhibitory polypeptide receptor agonists (eg, tirzepatide), hav…
Sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists have demonstrated renal benefits beyond glycemic control in patients with type 2 diabetes mellitus (T2DM). This study compares renal outcomes and…
BACKGROUND: Suboptimal initial clinical response (SICR) and weight gain recurrence (WGR) are challenging issues following bariatric surgery. Recently, the promising weight loss effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have bee…
BACKGROUND AND AIMS: Heart failure with preserved ejection fraction (HFpEF) remains a therapeutic challenge. GLP-1 receptor agonists (GLP-1RAs) show clinical promise, and the prevailing hypothesis is that their benefits are primarily driven by weight…
PURPOSE: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely prescribed, yet medication adherence varies. This study evaluated real-world adherence and persistence to semaglutide and e…
Obesity remains a critical global health issue with profound medical and economic implications. While injectable medications such as semaglutide (Wegovy®) and tirzepatide (Zepbound®) have demonstrated significant efficacy, the development of novel or…
Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have become central in managing obesity and type 2 diabetes, primarily through appetite suppression and metabolic regulation. This review explores the mechanisms underlying GLP-1 RA-induced weig…
BACKGROUND: Metabolic syndrome (MetS) represents a complex and multifaceted health condition characterized by a clustering of interconnected metabolic abnormalities, including central obesity, insulin resistance, dyslipidemia, and hypertension. Effec…
BACKGROUND: In the phase 3 ESSENCE clinical trial, semaglutide demonstrated improved histological outcomes for patients with metabolic dysfunction-associated steatohepatitis (MASH) with moderate or advanced fibrosis. There is limited real-world evide…
OBJECTIVE: To investigate the association between glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and ophthalmic adverse drug reactions (OADRs) using data from the FDA Adverse Event Reporting System (FAERS). METHODS: This retrospective pharmaco…
Diabetes mellitus is a global disease in which alterations in the internal environment disrupt the bone-fat balance, contributing to osteoporosis. Semaglutide, a single-target, long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has been…
BACKGROUND: Semaglutide 2·4 mg is approved for weight management in adults with obesity or overweight in the presence of at least one obesity-related complication; however, many people with obesity and type 2 diabetes do not reach their bodyweight re…